Assembly Biosciences ASMB Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Assembly Biosciences's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Assembly Biosciences's change in deferred revenue?
- Assembly Biosciences (ASMB) reported change in deferred revenue of -$7.83M in Q1 2026.
- How has Assembly Biosciences's change in deferred revenue changed year-over-year?
- Assembly Biosciences's change in deferred revenue increased by 16.9% year-over-year, from -$9.42M to -$7.83M.
- What is the long-term trend for Assembly Biosciences's change in deferred revenue?
- Over 2 years (2021 to 2025), Assembly Biosciences's change in deferred revenue has grown at a 140.2% compound annual growth rate (CAGR), from -$6.25M to -$36.1M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.